Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4756 AL 4770

Real-world evaluation of compliance and preference in Alzheimer's disease treatment

Pai MC, Aref H, Bassil N, Kandiah N, Lee JH, Srinivasan AV, diTommaso S, Yuksel O.

Clin Interv Aging. 2015 Nov 3;10:1779-87. doi: 10.2147/CIA.S85319. eCollection 2015.

Comparative study of the neuroprotective and nootropic activities of the carboxylate and amide forms of the HLDF-6 peptide in animal models of Alzheimer's disease

Bogachouk AP, Storozheva ZI, Solovjeva OA, Sherstnev VV, Zolotarev YA, Azev VN, Rodionov IL, Surina EA, Lipkin VM.

J Psychopharmacol. 2016 Jan;30(1):78-92. doi: 10.1177/0269881115616393. Epub 2015 Dec 1.

Downstream modulation of extrinsic apoptotic pathway in streptozotocin-induced Alzheimer's dementia in rats: Erythropoietin versus curcumin

Samy DM, Ismail CA, Nassra RA, Zeitoun TM, Nomair AM.

Eur J Pharmacol. 2016 Jan 5;770:52-60. doi: 10.1016/j.ejphar.2015.11.046. Epub 2015 Dec 2.

Herbal medicine Davaie Loban in mild to moderate Alzheimer's disease: A 12-week randomized double-blind placebo-controlled clinical trial

Tajadini H, Saifadini R, Choopani R, Mehrabani M, Kamalinejad M, Haghdoost AA.

Complement Ther Med. 2015 Dec;23(6):767-72. doi: 10.1016/j.ctim.2015.06.009. Epub 2015 Aug 29.

Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials

O'Regan J, Lanctôt KL, Mazereeuw G, Herrmann N.

J Clin Psychiatry. 2015 Nov;76(11):e1424-31. doi: 10.4088/JCP.14r09237.

Molecular Targets in Alzheimer's Disease: From Pathogenesis to Therapeutics

Cheng X, Zhang L, Lian YJ.

Biomed Res Int. 2015;2015:760758. doi: 10.1155/2015/760758. Epub 2015 Nov 19.

ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease

Shibuya Y, Chang CC, Chang TY.

Future Med Chem. 2015;7(18):2451-67. doi: 10.4155/fmc.15.161. Epub 2015 Dec 15.

The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis

Kobayashi H, Ohnishi T, Nakagawa R, Yoshizawa K.

Int J Geriatr Psychiatry. 2016 Aug;31(8):892-904. doi: 10.1002/gps.4405. Epub 2015 Dec 17.

[Coordinated care is paying off]

Rex C, Meier AG, Bischofberger I.

Krankenpfl Soins Infirm. 2015;108(7):14-6.

Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target?

St-Amour I, Cicchetti F, Calon F.

Acta Neuropathol. 2016 Apr;131(4):481-504. doi: 10.1007/s00401-015-1518-9. Epub 2015 Dec 21.

Accelerating stem cell trials for Alzheimer's disease

Hunsberger JG, Rao M, Kurtzberg J, Bulte JWM, Atala A, LaFerla FM, Greely HT, Sawa A, Gandy S, Schneider LS, Doraiswamy PM.

Lancet Neurol. 2016 Feb;15(2):219-230. doi: 10.1016/S1474-4422(15)00332-4. Epub 2015 Dec 17.

New Drugs from Marine Organisms in Alzheimer's Disease

Russo P, Kisialiou A, Lamonaca P, Moroni R, Prinzi G, Fini M.

Mar Drugs. 2015 Dec 25;14(1):5. doi: 10.3390/md14010005.

Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal Compounds

Singh SK, Srivastav S, Yadav AK, Srikrishna S, Perry G.

Oxid Med Cell Longev. 2016;2016:7361613. doi: 10.1155/2016/7361613. Epub 2015 Dec 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias